Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitor + Rosuvastatin on Liver Steatosis in Diabetic Post-PCI ACS Patients
NCT07736313Phase 3Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jul 2026
- Primary completion
- Sep 2028
01
Overview
Phase 3, randomised trial in acute coronary syndrome (ACS) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Assiut University. Primary endpoint: Change in liver structure assessed by Fibroscan at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
acute coronary syndrome (ACS)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07736313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07736313.